Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1996-05-01
1999-08-31
Criares, Theodore J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514444, 514443, 514663, 514673, 514579, A61K 3144, A61K 3138, A61K 3113, A61K 3116
Patent
active
059454326
ABSTRACT:
Methods and products are provided for treating thromboembolic stroke. A method involves the administration of a thienopyridine derivative in combination with a thrombolytic agent to a patient suffering from thromboembolic stroke. Preferably the thienopyridine derivative is ticlopidine and the thrombolytic agent is tPA. The method also involves the administration of a thrombolytic agent to a subject who already has circulating plasma levels of a thienopyridine derivative. The product is a pharmaceutical preparation of a thienopyridine derivative and a thrombolytic agent and a pharmaceutically acceptable carrier.
REFERENCES:
G. Roger Thomas, PhD, Harold Thibodeaux, BS, Carol J. Errett, Julie M. Badillo, BS, Bruce A. Keyt, PhD, Canio J. Refino, BS, Justin A. Zivin, MD, PhD, and William F. Bennett, PhD; "A Long-Half-life and Fibrin-Specific Form of Tissue Plasminogen Activator in Rabbit Models of Embolic Stroke and Peripheral Bleeding"; Stroke, vol. 25, No. 10, Oct. 1994, pp. 2072-2079.
Charles E. Hennekens, MD, Christopher J. O'Donnell, MD, Paul M. Ridker, MD, and Victor J. Marder, MD; "Current Issues Concerning Thrombolytic Therapy for Acute Myocardial Infarction"; JACC, vol. 25, No. 7 (Supplement), Jun. 1995, pp. 18S-22S.
David R. Holmes, Jr., MD, Robert M. Califf, MD, and Eric J. Topol, MD; "Lessons We Have Learned From the GUSTO Trial"; JACC, vol. 25, No. 7 (Supplemental), Jun. 1995, pp. 10S-17S.
Martin M. Bednar, Richard H. Dooley, Maziar Zamani, Diantha B. Howard, and Cordell E. Gross; "Neutrophil and Platelet Activity and Quantification Following Delayed tPA Therapy in a Rabbit Model of Thromboembolic Stroke"; Journal of Thrombosis and Thrombolysis 1995, pp. 179-185.
G. Roger Thomas, PhD, Harold Thibodeaux, BS, Carol J. Errett, Martin M. Bednar, MD, PhD, Cordell E. Gross, MD, and William F. Bennett, PhD; "Intravenous Aspirin Causes a Paradoxical Attenuation of Cerebrovascular Thrombolysis", Stroke, vol. 26, No. 6, Jun. 1995, pp. 1039-1046.
Robert G. Hart, MD, Dianne H. Solomon, MD, J. James Rohack, MD, and William M. Feinberg, MD; "What's new in stroke?"; Texas Medicine, vol. 91, No. 5, May 1995, pp. 46-55.
Peggy Jo Donahue; "Head Off A Stroke; A New Guide To Clot-Dissolving Drugs", Prevention Magazine, 1988, pp. 39-45.
William Feinberg, MD; "Antithrombotic Therapy in Stroke and Transient Ischemic Attacks"; AFP, vol. 40, No. 5, (Supplement), Nov. 1989, pp. 53S-59S.
Jawed Fareed, Demetra D. Callas, Debra Hoppensteadt, Walter Jeske & Jeanine M. Walenga; "Recent developments in antithrombotic agents"; Exp. Opin. Invest. Drugs (1995) 4(5), pp. 389-412.
Sheng-Kun Yao, Judy C. Ober, James J. Ferguson, Jean-Pierre Maffrand, H. Vernon Anderson, L. Maximilian Buja, and James T. Willerson; "Clopidogrel is more effective than aspirin as adjuvant treatment to prevent reocclusion after thrombolysis"; Clopidogrel, Thrombolysis, and Reocclusion, American Physiological Society, 1994, pp. H488-H493.
Richard C. Becker, MD and Jack Ansell, MD; "Antithrombotic Therapy", Arch. Intern. Med., vol. 155, Jan. 23, 1995, pp. 149-161.
Marc Verstraete and Pierre Zoldhelyi; "Novel Antithrombotic Drugs in Development"; Drugs 49(6), 1995, pp. 856-884.
Joan C. Murray, Michael A. Kelly, and Philip B. Gorelick; "Ticlopidine: A New Antiplatelet Agent for the Secondary Prevention of Stroke"; Clinical Neuropharmacology, vol. 17, No. 1, 1994, pp. 23-31.
Charles Warlow, "Ticlopidine, a new antithrombotic drug; but is it better than aspirin for longterm use?"; Journal of Neurology, Neurosurgery & Psychiatry, pp. 185-187.
Karsten Schror; "Antiplatelet Drugs A Comparative Review"; Drugs 50(1), 1995, pp. 7-28.
Gerard Besson and Julien Bogousslavsky; "Current and Future Options for the Prevention and Treatment of Stroke"; CNS Drugs 3(5), 1995, pp. 351-362.
A. Bernat, F. Dol, J.M. Herbert, M. Sainte-Marie and J.P. Maffrand; "Potentiating Effects of Anticoagulants and Antiplatelet Agents on Streptokinase Thrombolysis in the Rabbit"; Fibrinolysis, Gregory No. 7, 1993, pp. 23-30.
Gregory J. Del Zoppo, MD, Brian R. Copeland, MD, Laurence A. Harker, MD, Thomas A. Waltz, MD, Jack Zyroff, MD and Stephen R. Hanson, PhD; "Experimental Acute Thrombotic Stroke in Babboons"; Stroke, vol. 17, No. 6, Nov.-Dec. 1986, pp. 1254-1265.
David G. Sherman, MD, Mark L. Dyken, Jr., MD, Marc Fisher, MD, Michael Gent, PhD, Michael Harrison, MD, and Robert G. Hart, MD; "Antithrombotic Therapy for Cerebrovascular Disorders"; Chest, 102, 4, (Supplement), Oct. 1992, pp. 529S-537S.
Gregory W. Albers; "Antithrombotic Agents in Cerebral Ischemia"; The American Journal of Cardiology, vol. 75, Feb. 23, 1995, pp. 34B-38B.
Martin M. Bednar, MD, Timothy McAuliffe, PhD, Sheila Raymond, AS, and Cordell E. Gross, MD; "Tissue Plasminogen Activator Reduces Brain Injury in a Rabbit Model of Thromboembolic Stroke"; Stroke, vol. 21, No. 12, Dec. 1990, pp. 1705-1709.
Martin M. Bednar, Sheila J. Raymond, and Cordell E. Gross; "Tissue plasminogen activator; Comparison of dose and route of administration in a rabbit model of thromboembolic stroke"; 4 pp.
Cordell E. Gross, MD, Sheila J. Raymond, A.S., Diantha B. Howard, M.S., and Martin J. Bednar, MD; "Delayed Tissue-Plasminogen Activator Therapy in a Rabbit Model of Thromboembolic Stroke"; Neurosurgery, vol. 36, No. 6, Jun. 1995, pp. 1172-1177.
Cordell E. Gross, Diantha B. Howard, Richard H. Dooley, Sheila J. Raymond, Susan Fuller and Martin M. Bednar; "TGF-.beta.1post-treatment in a rabbit model of cerebral ischaemia"; 5 pp.
William F. Bennett, Nicholas F. Paoni, Bruce A. Keyt, David Botstein, Andrew J.S. Jones, Leonard Presta, Florian M. Wurm, and Mark J. Zoller; "High Resolution Analysis of Functional Determinants on Human Tissue-type Plasminogen Activator"; The Journal of Biological Chemistry, vol. 266, No. 8, Mar. 15, 1991, pp. 5191-5201.
Suguru Suzuki, Mamoru Saito, Noboru Suzuki, Hiroyuki Kato, Naoko Nagaoka, Shinji Yoshitake, Yoshi Yui, and Chuichi Kawai, "Intracoronary Infusion of E6010 has More Potent Thrombolytic Activity Than Tissue Plasminogen Activator (t-PA) in Dogs; A Higher Plasma Level of E6010 Than t-PA Causes Potent Thrombolytic Activity"; Journal of Cardiovascular Pharmacology, vol. 22, No. 6, 1993, pp. 834-840.
Peter J. Bugelski, Kei-Lai L. Fong, Anne Klinkner, Janice Sowinski, Glenn Rush and D. Gwyn Morgan; "Uptake of Human Recombinant Tissue-Type Plasminogen Activator by Rat Hepatocytes In Vivo; An Electron Microscope Autoradiographic Study"; Thrombosis Research, vol. 53, No. 3, 1989, pp. 287-303.
J.H. Verheijen, M.P.M. Caspers, G.T.G. Chang, G.A.W. de Munk, P.H. Pouwels, and B.E. Enger-Valk; "Involvement of finger domain and kringle 2 domain of tissue-type plasminogen activator in fibrin binding and stimulation of activity by fibrin"; The EMBO Journal, vol. 5, No. 13, 1986, pp. 3525-3530.
Glenn R. Larsen, Mark Metzger, Kimberlee Henson, Yitzhak Blue, and Patricia Horgan; "Pharmacokinetic and Distribution Analysis of Variant Forms of Tissue-Type Plasminogen Activator With Prolonged Clearance in Rat"; Blood, vol. 73, No. 7, May 15, 1989, pp. 1842-1850.
Douglas E. Vaughan, Paul J. Declerck, Maria De Mol, and Desire Collen; "Recombinant Plasminogen Activator Inhibitor-1 Reverses the Bleeding Tendency Associated with the Combined Administration of Tissue-type Plasminogen Activator and Aspirin in Rabbits"; J. Clin. Invest., vol. 84, Aug. 1989, pp. 586-591.
Phillip A. Morton, Dwain A. Owensby, Burton E. Sobel, and Alan L. Schwartz; "Catabolism of Tissue-type Plasminogen Activator by the Human Hepatoma Cell Line Hep G2"; The Journal of Biological Chemistry, vol. 264, No. 13, May 5, 1989, pp. 7228-7235.
Burton E. Sobel, MD, Stanley J. Sarnoff, MD, and Denise A. Nachowiak, BA; "Augmented and Sustained Plasma Concentrations After Intramuscular Injections of Molecular Variants and Deglycosylated Forms of Tissue-Type Plasminogen Activators"; Circulation, vol. 81, 1990, pp. 1362-1373.
Burton E. Sobel, MD, Edward M. Geltman, MD, alan J. Tiefenbrunn, MD, Allan S. Jaffe, MD, James J. Spadaro, Jr., MD, Michel M. Ter-Pogossian, PhD, Desire Collen, MD, and Philip A. Ludbrook, MB, BS; "Improvement of regional my
Bednar Martin M.
Gross Cordell E.
Keyt Bruce A.
Criares Theodore J.
Grenentech, Inc.
The University of Vermont and State Agricultural College
LandOfFree
Thrombolytic agents and thienopyridine derivatives in acute stro does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Thrombolytic agents and thienopyridine derivatives in acute stro, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thrombolytic agents and thienopyridine derivatives in acute stro will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2426593